Story

The article traces the history of GLP-1 agonists, a class of diabetes drugs, highlighting the work of researchers John Baxter and Jeffrey Flier. It explores how Baxter's initial discoveries at Pfizer led to the development of successful GLP-1 drugs, while Flier's research at Harvard Medical School contributed to the understanding of the underlying science.